A revised Paxlovid supply agreement with the U.S. government has pushed Pfizer to launch a “cost realignment” program including layoffs, though it is still unclear how many employees will be affected.
Today Pfizer announced the FDA’s approval of VELSIPITY, an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for adults with moderately to severely active ulcerative colitis (UC), a condition that produces debilitating symptoms such as chronic diarrhea with blood and mucus, abdominal pain, and urgency and affects approximately 1.25 million people in the United States.
The European Union medicines regulator recommended a conditional marketing authorization for U.S. drugmaker Pfizer’s therapy for a type of blood cancer that is difficult to treat.
Lawsuits by the wholesalers, as well as by consumers, followed a public outcry in 2016 after Mylan, which owns the rights to market and distribute the devices, raised the price of a pair of EpiPens to $600, from $100 in 2008.
The U.S. health regulator did not find any misconduct at clinical sites managed by Care Access for Pfizer (PFE.N) and French partner Valneva’s (VLS.PA) trial of a Lyme disease vaccine candidate, the contract research firm stated.
As the COVID-19 pandemic continues to recede, the top pharma companies intensified their focus into areas such as cancer and metabolic diseases to build up their pipelines, and their growth prospects, for the future.
Pfizer’s mRNA vaccine, Comirnaty, was the company’s highest-selling product once again, but leaders are looking to the Seagen acquisition for future growth.
British drugmaker GSK on Friday said it raised 885.6 million pounds ($1.08 billion) from a discounted stake sale in Haleon, cutting its shareholding to 7.4% in the world’s largest standalone consumer healthcare firm.
Pfizer, BioNTech, and biotech firm Promosome told a federal judge in San Diego, California that they have agreed to end Promosome’s lawsuit accusing the COVID-19 vaccine makers of infringing a patent related to messenger RNA technology.
Around 4 million Americans received the updated COVID-19 shots in September, according to the U.S. Department of Health and Human Services (HHS), even as some people have found it difficult to book vaccination appointments or find the vaccines at no cost.